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Background: Comorbidities can occur frequently in patients with chronic obstructive pulmonary 
disease (COPD) and can influence mortality and morbidity independently. It is increasingly 
recognized that many patients with COPD have comorbidities that have a major impact on 
their quality of life and survival. Therefore, we investigated the prevalence of comorbidities in 
Korean COPD populations.
Methods: We used data obtained in the 6 years of the fourth and fifth Korean National Health 
and Nutrition Examination Survey (KNHANES) IV and V. Among 50,405 subjects, 16,151 
subjects aged $40 years who performed spirometry adequately were included in this study. Air-
way obstruction was defined as forced expiratory volume in 1 second/forced vital capacity ,0.7, 
and the Global Initiative For Chronic Obstructive Lung Disease stage was used to evaluate the 
severity of airway obstruction. Statistical analyses were performed using SAS 9.2.
Results: Among the 16,151 subjects (43.2% male, 56.8% female; mean age: 57.1 years for 
men and 57.2 years for women), 13.1% had obstructive lung function; 11.3%, restrictive lung 
function; and 75.6%, normal lung function. Among individuals with obstructive lung function, 
45.3%, 49.4%, and 5.3% had mild, moderate, and severe and very severe airflow limitation. The 
prevalence of hypertension, diabetes mellitus (DM), underweight, and hypertriglyceridemia was 
higher in the obstructive lung function group than in the normal lung function group (49.6% vs 
35.2%; 16.8% vs 10.5%; 3.3% vs 1.3%; 19.7% vs 17.0%). According to the severity of airway 
obstruction, hypertension and underweight were more common as severity increased, although 
the prevalence of DM and hypertriglyceridemia was lower in subjects with severe airway obstruc-
tion. The prevalence of hypercholesterolemia, overweight, and osteoarthritis was lower in the 
obstructive lung function group, especially in the severe airway obstruction groups.
Conclusions: Overall, our analysis is similar to research that was conducted earlier. Our study 
showed that hypertension and underweight are common comorbidities in COPD patients, and 
are higher as the severity of airflow obstruction increased in both men and women. DM, hyper-
triglyceridemia, and low high-density lipoprotein cholesterol are more common in subjects with 
airway obstruction, although their incidence is lower in the severe group.
Keywords: chronic obstructive pulmonary disease, comorbidity, hypertension, underweight
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by persistent air-
flow limitation that is usually progressive.1 COPD is a major cause of morbidity and 
mortality around the world.2 The frequencies of other causes of death are expected 
to decrease in the future, whereas COPD is expected to have a significant impact on 
morbidity, mortality, and health costs worldwide.3 Patients with COPD frequently 
show cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, 
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osteoporosis, depression, and lung cancer. These can influ-
ence mortality and morbidity independently, so they should 
be actively looked for and treated appropriately if present.1,4 
However, these comorbidities are reported to occur mainly in 
the West, and there are few studies of COPD comorbidities 
among Asian patient populations. Therefore, we investigated 
the prevalence of COPD comorbidities using the data from 
the fourth and the fifth Korean National Health and Nutrition 
Examination Survey (KNHANES).
Material and methods
study design
We retrospectively analyzed the database of the fourth and fifth 
(2007–2012) KNHANES, a nationally representative stratified 
random sample of 50,405 subjects who were selected from 
the Korean population. The KNHANES database included the 
results of various health-related questionnaires (eg, smoking 
history, income status, various diseases) by trained interview-
ers; physical examination (eg, blood pressure, body weight, 
height); laboratory studies (eg, complete blood cell, routine 
chemistry, lipid profile); image studies (eg, bone mineral 
density, joint X-ray); and pulmonary function test (PFT). Of 
these, 16,151 were aged $40 years and underwent acceptable 
PFT. Finally, these latter subjects were used to analyze the 
prevalence of COPD and the comorbidities (Figure 1). But we 
inevitably included subjects with airway obstruction caused by 
other diseases, such as asthma, pulmonary tuberculosis, and 
bronchiectasis, because it was not possible to exclude these 
diseases using inaccurate self-reported physician diagnosis 
criteria. So we just described these diseases and comorbidi-
ties according to a self-reported questionnaire through our 
available data on Table S1.
spirometry
Pulmonary function testing was carried out by trained medical 
personnel using dry rolling seal spirometers (SensorMedics, 
Model 2130; Yorba Linda, CA, USA), which met the 
performance criteria of the American Thoracic Society/
European Respiratory Society (ATS/ERS).5 We analyzed 
prebronchodilator data from subjects aged $40 years that 
performed spirometry adequately.
Definition of COPD and the severity of 
airflow limitation
Airflow limitation was defined as forced expiratory volume 
in 1 second/forced vital capacity FEV
1
/FVC (%FEV
1
) ,0.7. 
.1+$1(6,9±91 
$JHG\HDUV1 
1R3)7RULQDGHTXDWH3)7GDWD1 
(OLJLEOHVXEMHFWVDJHG\HDUVDQGXQGHUJRLQJDFFHSWDEOH3)71 
1RUPDOSDWWHUQ1  5HVWULFWLYHSDWWHUQ1  2EVWUXFWLYHSDWWHUQ1 
Figure 1 Flowchart for selection of study subjects.
Notes: normal pattern = FeV1/FVC $70% and FeV1 $80% predicted; restrictive pattern = FeV1/FVC $70% and FeV1 ,80% predicted; obstructive pattern = FeV1/FVC ,70%.
Abbreviations: Knhanes, Korean national health and nutrition examination survey; PFT, pulmonary function test; FeV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity.
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And COPD was defined as airflow limitation in subjects 
aged $40 years. The severity of airflow limitation was 
classified according to GOLD (Global Initiative for Chronic 
Obstructive Lung Disease)1 criteria as follows:
•	 Mild: FEV
1
 $80% predicted
•	 Moderate: 50% predicted # FEV
1
 ,80% predicted
•	 Severe: FEV
1
 ,50% predicted.
Definition of comorbidities
Hypertension, diabetes mellitus (DM), anemia, dyslipidemia, 
obesity, osteopenia and osteoporosis, osteoarthritis were 
defined as follows:
1. Hypertension: systolic blood pressure $140 mmHg or 
diastolic blood pressure $90 mmHg, or on medication
2. DM: fasting blood glucose $126 mg/dL or on diabetes 
medication or insulin injections
3. Anemia: hemoglobin (Hb) ,12 g/L in nonpregnant women 
aged $15 years; Hb ,11 g/L in pregnant women and 
aged $15 years; Hb ,13 g/L in men aged $15 years
4. Dyslipidemia: defined as inclusion of one or more of the 
following; hypercholesterolemia, hypertriglyceridemia, 
low HDL (high-density lipoprotein) cholesterol, and high 
LDL (low-density lipoprotein) cholesterol
•	 Hypercholesterolemia: fasting total cholesterol 
$240 mg/dL or on medication
•	 Hypertriglyceridemia: serum triglyceride level 
$200 mg/dL after fasting more than 12 hours
•	 Low HDL cholesterol: serum HDL cholesterol level 
,40 mg/dL after fasting more than 8 hours
•	 High LDL cholesterol: (total cholesterol – HDL 
cholesterol – triglyceride ×1/5) $130 mg/dL
5. Obesity: underweight (body mass index ,18.5 kg/m2), 
normal (18.5 kg/m2 # body mass index ,23.0 kg/m2), 
overweight (body mass index $ 23.0 kg/m2) according 
to the Asian body mass index cutoff by WHO expert 
consultation6
6. Osteopenia (-2.5, T-score ,-1.0) and Osteoporosis 
(T-score #-2.5): T-score was examined for the lumbar 
region, entire femur, and femoral neck in postmenopausal 
women and men aged $50 years
7. Osteoarthritis: $50 years old and Kellgren–Lawrence 
grade of knee or hip joint $2. The Kellgren–Lawrence 
grade system is a method of classifying the severity of knee 
osteoarthritis using five grades as follows: “grade 0” = no 
radiologic features of osteoarthritis are present; “grade 1” = 
doubtful joint space narrowing and possible osteophytic 
lipping; “grade 2” = define osteophytes and possible 
joint space narrowing on anteroposterior weight-bearing 
radiograph; “grade 3” = multiple osteophytes, definite 
joint space narrowing, sclerosis, possible bony deformity; 
“grade 4” = large osteophytes, marked joint space narrow-
ing, severe sclerosis, and definite bony deformity.
statistical analysis
All values are expressed as means ± standard deviation. The 
cross-sectional analysis and chi-square test were used to estab-
lish the prevalence of comorbid disease among subjects with 
and without COPD. A P-value of less than 0.05 was defined 
as statistically significant. Statistical analyses were carried out 
using SAS 9 (SAS Institute Inc. Cary, NC, USA).
ethics statement
The Korea Center for Disease Control and Prevention 
(KCDC) Institutional Reviews Board approved all survey 
protocols (numbers 2007-02CON-04-P, 2008-04EXP-010C, 
2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-
06-C, 2012-01EXP-01-2C), and participants provided 
informed consent before partaking in the study, which was 
conducted in accordance with the ethical principles of the 
Declaration of Helsinki.
Results
Characteristics of the subjects
Among 50,405 subjects, a subgroup of 16,151 individu-
als aged $40 years who performed spirometry adequately 
were included in this study. Among these subjects, 13.1% 
had obstructive lung function, 11.3% had restrictive lung 
function, and 75.6% had normal lung function (Figure 1). 
Of the 16,151 subjects (43.2% male, 56.8% female; mean age: 
57.1 years for men and 57.2 years for women), 21.0% were 
current smokers, 9.6% were ex-smokers, and 69.4% were 
never smokers. On average, all subjects smoked 6.6 pack-
years. Subjects who were male, of older age, smokers, and 
reported having low income were more common in the COPD 
group than in the normal lung function group (Table 1).
Comorbidities of COPD subjects
When compared with the normal lung function group, 
subjects in the obstructive lung function group had a higher 
prevalence of hypertension, DM, hypertriglyceridemia, low 
HDL cholesterol, and low body mass index (BMI ,18.5). 
Conversely, overweight (BMI $23.0), osteoarthritis, hyper-
cholesterolemia, high LDL cholesterol, and anemia were less 
common in the obstructive lung function group than in the 
normal lung function group. In the case of osteoporosis, there 
was no great difference between the two groups (Table 2).
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Table 1 Baseline characteristics of study population
Characteristics Normal Restrictive Obstructive Obstructive severity Total
Mild Moderate Severe
12,224 (75.6%) 1,819 (11.3%) 2,108 (13.1%) 954 (45.3%) 1,042 (49.4%) 112 (5.3%) 16,151 (100.0%)
age (years) 55.8±10.7 60.4±10.9 64.5±10.2 65.8±10.1 63.2±10.3 65.9±9.2 57.5±11.1
age group (years)
40–49 (%) 4,066 (33.3) 350 (19.3) 203 (9.7) 72 (7.5) 125 (12.0) 6 (5.3) 4,619 (28.6)
50–59 (%) 3,826 (31.3) 481 (26.4) 433 (20.5) 182 (19.1) 230 (22.1) 21 (18.8) 4,740 (29.3)
60–69 (%) 2,741 (22.4) 559 (30.7) 730 (34.6) 315 (33.0) 378 (36.3) 37 (33.0) 4,030 (25.0)
$70 (%) 1,591 (13.0) 429 (23.6) 742 (35.2) 385 (40.4) 309 (29.7) 48 (42.9) 2,762 (17.1)
sex
Male 4,695 (38.4) 849 (46.7) 1,434 (68.0) 664 (69.6) 695 (66.7) 75 (67.0) 6,978 (43.2)
Female 7,529 (61.6) 970 (53.3) 674 (32.0) 290 (30.4) 347 (33.3) 37 (33.0) 9,173 (56.8)
smoking statusa
never 7,920 (73.6) 1,057 (71.1) 667 (42.8) 284 (42.1) 355 (44.7) 28 (31.8) 9,644 (69.4)
Former 866 (8.1) 191 (12.8) 274 (17.6) 115 (17.0) 133 (16.8) 26 (29.6) 1,331 (9.6)
Current 1,973 (18.3) 329 (22.1) 616 (39.6) 276 (40.9) 306 (38.5) 34 (38.6) 2,918 (21.0)
Pack-year 5.3±12.9 7.5±16.5 15.5±20.7 14.8±19.9 15.8±20.9 19.7±25.0 6.6±14.6
household income (quartile)a
First quartile 2,491 (20.6) 505 (28.2) 698 (33.7) 332 (35.5) 316 (30.9) 50 (45.9) 3,694 (23.2)
second quartile 3,012 (25.0) 423 (23.6) 546 (26.4) 223 (23.8) 297 (29.0) 26 (23.9) 3,981 (25.0)
Third quartile 3,041 (25.2) 422 (23.6) 418 (20.2) 180 (19.2) 219 (21.4) 19 (17.4) 3,881 (24.4)
Fourth quartile 3,522 (29.2) 440 (24.6) 407 (19.7) 201 (21.5) 192 (18.8) 14 (12.8) 4,369 (27.4)
Notes: Data are presented as numbers (percentages) for categorical variables. Continuous variables are presented as means ± standard deviations. aThe sums of some data 
do not equal the total due to missing data; normal = FeV1/FVC $70% and FeV1 $80% predicted; restrictive = FeV1/FVC $70% and FeV1 ,80% predicted; obstructive = FeV1/
FVC ,70% predicted; mild = FeV1 $80% predicted; moderate =50% # FeV1 ,80% predicted; severe = FeV1 ,50% predicted.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
Table 2 Comorbidities according to lung function
Comorbidity Normal Restrictive Obstructive Obstructive severity P-value
Mild Moderate Severe
12,224 (75.6%) 1,819 (11.3%) 2,108 (13.1%) 954 (45.3%) 1,042 (49.4%) 112 (5.3%)
hypertension 4,237 (35.2) 936 (52.2) 1,035 (49.6) 456 (48.2) 519 (50.4) 60 (54.1) ,0.001
DM 1,206 (10.5) 345 (20.4) 329 (16.8) 137 (15.6) 178 (18.2) 14 (13.9) ,0.001
anemia 1,028 (8.7) 176 (10.2) 153 (7.6) 73 (8.0) 71 (7.1) 9 (8.5) 0.074
Dyslipidemia 6,982 (70.0) 1,128 (76.6) 1,253 (72.7) 557 (71.0) 642 (64.3) 54 (64.3) ,0.001
hypercholesterolemia 1,964 (17.1) 354 (21.0) 305 (15.6) 122 (13.9) 170 (17.4) 13 (13.0) ,0.001
hypertriglyceridemia 1,640 (17.0) 299 (21.6) 337 (19.7) 150 (19.3) 175 (20.8) 12 (13.3) ,0.001
low hDl cholesterol 2,742 (25.1) 522 (32.9) 635 (34.0) 296 (35.1) 310 (33.3) 29 (31.2) ,0.001
high lDl cholesterol 3,846 (35.8) 515 (33.2) 554 (30.6) 232 (28.8) 294 (32.1) 28 (31.5) ,0.001
Obesity
18.5 kg/m2 . BMI 153 (1.2) 31 (1.7) 70 (3.3) 18 (1.9) 33 (3.2) 19 (17.4) ,0.001
18.5 kg/m2 # BMI ,23.0 kg/m2 7,616 (62.4) 832 (46.2) 1,435 (68.2) 691 (72.4) 671 (64.4) 73 (67.0)
23.0 kg/m2 # BMI 4,437 (36.4) 939 (52.1) 600 (28.5) 245 (25.7) 338 (32.4) 17 (15.6)
Osteoporosisa
Osteopenia 406 (5.0) 63 (4.3) 51 (2.7) 19 (2.2) 29 (3.2) 3 (2.8) 0.954
Osteoporosis 223 (2.7) 36 (4.3) 35 (2.7) 12 (1.4) 20 (2.2) 3 (2.8)
Osteoarthritisa 1,040 (12.7) 200 (13.6) 226 (11.9) 121 (13.7) 98 (10.7) 7 (6.6) ,0.001
Notes: Data are presented as numbers (percentages) for categorical variables. aData do not equal the total because evaluations for osteoporosis and osteoarthritis were 
only performed in subjects aged $50 years (normal =8,158; restrictive =1,469; obstructive =1,905; mild =882; moderate =917; severe =106); normal = FeV1/FVC $70% and 
FeV1 $80% predicted; restrictive = FeV1/FVC $70% and FeV1 ,80% predicted; obstructive = FeV1/FVC ,70% predicted; Mild = FeV1 $80% predicted; moderate =50% # 
FeV1 ,80% predicted; severe = FeV1 ,50% predicted.
Abbreviations: BMI, body mass index; DM, diabetes mellitus; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; hDl, high density lipoprotein; lDl, 
low density lipoprotein.
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Comorbidities according to sex and lung 
function in subjects with obstructive 
airflow limitation
We analyzed comorbidities according to sex and the severity 
of COPD. Among individuals with obstructive lung function, 
45.3% had mild disease, 49.4% had moderate disease, and 
5.3% had severe disease. Hypertension was more common 
as the airway limitation became more severe. Although 
the prevalence of DM, hypertriglyceridemia, hypercho-
lesterolemia, and overweight were lower in subjects with 
severe airway obstruction, the prevalence of underweight 
increased, but low HDL cholesterol decreased with the 
severity of obstruction. On the other hand, the prevalence of 
osteoarthritis decreased with increasing severity of airway 
obstruction. Osteoporosis seemed to have a higher prevalence 
as the severity of obstruction increased, but the prevalence of 
osteopenia in the groups with more severe disease was lower 
than that in the normal lung function group (Table 2).
When the subjects were divided into men and women, 
the numbers of ever smokers (50.9% vs 23.7%), DM (17.3% 
vs 12.0%), hypertriglyceridemia (17.6% vs 12.6%), and 
low HDL cholesterol (35.0% vs 19.7%) were higher in men 
with obstructive lung function than in women with obstruc-
tive lung function. In contrast, women with obstructive 
lung function more frequently had hypercholesterolemia 
(18.0% vs 12.8%), high LDL cholesterol (31.9% vs 23.6%), 
osteoarthritis (18.3% vs 8.9%), anemia (9.5% vs 6.2%), 
and osteoporosis (5.0% vs 1.0%) (Table 3). Hypertension, 
underweight, overweight, and osteoarthritis showed similar 
trends between men and women (Figure 2). However, there 
were differences in trends for dyslipidemia between men and 
women. In men, the prevalence of all kinds of dyslipidemia 
decreased in the severe obstructive lung function group; in 
women, the prevalence of dyslipidemia increased rather than 
decreased in the severe obstructive lung function group, with 
the exception of hypercholesterolemia (Figure 3A–D).
Discussion
Most COPD patients also show other diseases that may 
affect the prognosis. Compared with patients without COPD, 
patients with COPD had more than twice the number of 
comorbidities, longer hospital stays, and higher in-hospital 
mortality rates. Some of these diseases are independently 
generated, regardless of COPD, but some others share risk 
factors, such as smoking, or increase the risk of one another. 
Systemic inflammation, which is characteristic of COPD, 
is common in other comorbidities, and is thought to be the 
mechanism that connects COPD with other comorbidities.7 
Because COPD often develops in long-time smokers in 
middle age, patients frequently have a variety of other dis-
eases related to either smoking or aging.8 COPD itself also 
has significant extrapulmonary effects including weight loss, 
nutritional abnormalities, and skeletal muscle dysfunction. It 
can contribute to exercise intolerance and poor health status 
in patients with COPD.9
In this study, as in the previous study, hypertension, DM, 
and dyslipidemia were more common in COPD patients. 
However, when we divided the subjects by severity and sex, 
the results of this study were rather dissimilar to those of the 
previous study.
In COPD subjects, the prevalence of obesity was 23%.10–13 
The mean BMI was .25 kg/m2 in Western countries, 
including Austria, Germany, Canada, and the United States, 
whereas in the People’s Republic of China and the Philip-
pines, mean BMI of COPD subjects was 23.3 and 24.9 kg/m2, 
respectively.14 In a previous study in Korea, obesity (BMI 
$23 kg/m2) was observed in 23.5% of COPD patients.15 
In our study, prevalence of obesity (BMI $23 kg/m2) was 
28.5%, and mean BMI was 24.2 kg/m2. Prevalence of obesity 
and mean BMI can vary depending on country and race. 
However, most available data suggest that obesity is more 
prevalent in patients with COPD than in the general popu-
lation, depending on the severity of chronic airflow limita-
tion; an exception was the study by Steuten et al16 who had 
reported that the rate of obesity decreased in subjects with 
severe airway obstruction. As in our study, a previous study 
reported in Korea showed that subjects with airway obstruc-
tion had lower BMI and fat free mass index values, and the 
reductions were prominent in subjects with severe airway 
obstruction.17 These data showed the pathognomonic rela-
tionship between BMI and the degree of airway obstruction 
in Asians, including Koreans. Increased work of breathing, 
higher total daily energy expenditure, catabolic energy bal-
ances, and systemic inflammatory responses can be causes of 
low BMI.18–20 Moreover, low BMI can also be an independent 
risk factor for mortality in patients with COPD.21,22 Therefore, 
physicians should pay more attention to the nutritional and 
functional status of patients with COPD.
Cardiovascular disease is the most important and the 
most frequent comorbidity in COPD.8 Hypertension is the 
most important factor in cardiovascular disease, and it has a 
major influence on prognosis.7 In Western countries, approxi-
mately 17%–55% of COPD patients had hypertension;12,23–28 
a previous study in Korea reported a prevalence of 39.4%.15 
Although in COPD patients, the mechanism of cardiovascu-
lar disease – including hypertension – is not yet quite clear, 
International Journal of COPD 2015:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1576
Park et al
T
ab
le
 3
 C
om
or
bi
di
tie
s 
ac
co
rd
in
g 
to
 s
ex
 a
nd
 lu
ng
 fu
nc
tio
n 
in
 s
ub
je
ct
s 
w
ith
 o
bs
tr
uc
tiv
e 
ai
rfl
ow
 li
m
ita
tio
n
Se
x
M
al
e
Fe
m
al
e
O
bs
tr
uc
ti
ve
 s
ev
er
it
y
T
ot
al
M
ild
M
od
er
at
e
Se
ve
re
P-
va
lu
e
T
ot
al
M
ild
M
od
er
at
e
Se
ve
re
P-
va
lu
e
C
om
or
bi
di
ty
1,
43
4
66
4 
(9
.5
%
)
69
5 
(1
0.
0%
)
75
 (
1.
1%
)
67
4
29
0 
(3
.1
6%
)
34
7 
(3
.7
8%
)
37
 (
0.
40
%
)
sm
ok
in
g 
st
at
us
a
n
ev
er
18
4 
(1
2.
8)
81
 (
20
.1
)
95
 (
20
.7
)
8 
(0
.2
)
,
0.
00
1
48
3 
(7
1.
7)
20
3 
(7
4.
9)
26
0 
(7
7.
4)
20
 (
55
.6
)
,
0.
00
1
Fo
rm
er
21
4 
(1
4.
9)
93
 (
23
.0
)
10
2 
(2
2.
3)
19
 (
36
.5
)
60
 (
8.
9)
22
 (
8.
1)
31
 (
9.
2)
7 
(1
9.
4)
C
ur
re
nt
51
6 
(3
6.
0)
23
0 
(5
6.
9)
26
1 
(5
7.
0)
25
 (
48
.1
)
10
0 
(1
4.
8)
46
 (
17
.0
)
45
 (
13
.4
)
9 
(2
5.
0)
h
yp
er
te
ns
io
n
71
8 
(5
0.
1)
32
6 
(4
9.
 6
)
35
3 
(5
1.
3)
39
 (
52
.7
)
,
0.
00
1
31
7 
(4
7.
0)
13
0 
(4
5.
3)
16
6 
(4
8.
5)
21
 (
56
.8
)
,
0.
00
1
D
ia
be
te
s 
M
el
lit
us
24
8 
(1
7.
3)
10
1 
(1
6.
2)
13
6 
(2
0.
6)
11
 (
16
.7
)
,
0.
00
1
81
 (
12
.0
)
36
 (
14
.0
)
42
 (
13
.2
)
3 
(8
.6
)
,
0.
00
1
a
ne
m
ia
89
 (
6.
2)
41
 (
6.
4)
43
 (
6.
4)
5 
(7
.0
)
,
0.
00
1
64
 (
9.
5)
32
 (
11
.8
)
28
 (
8.
5)
4 
(1
1.
4)
0.
40
9
D
ys
lip
id
em
ia
h
yp
er
ch
ol
es
te
ro
le
m
ia
18
4 
(1
2.
8)
77
 (
12
.4
)
10
1 
(1
5.
3)
6 
(9
.1
)
0.
11
1
12
1 
(1
8.
0)
45
 (
17
.7
)
69
 (
21
.7
)
7 
(2
0.
6)
,
0.
00
1
h
yp
er
tr
ig
ly
ce
ri
de
m
ia
25
2 
(1
7.
6)
10
8 
(1
9.
9)
13
8 
(2
4.
3)
6 
(1
0.
2)
0.
00
9
85
 (
12
.6
)
42
 (
18
.0
)
37
 (
13
.5
)
6 
(1
9.
4)
0.
01
5
lo
w
 h
D
l 
ch
ol
es
te
ro
l
50
2 
(3
5.
0)
23
4(
38
.4
)
24
7 
(3
8.
2)
21
 (
33
.3
)
,
0.
00
1
13
3 
(1
9.
7)
62
 (
26
.7
)
63
 (
22
.1
)
8 
(2
6.
7)
,
0.
00
1
h
ig
h 
lD
l 
ch
ol
es
te
ro
l
33
9 
(2
3.
6)
14
8 
(2
5.
9)
17
5 
(2
8.
3)
16
 (
25
.8
)
,
0.
00
1
21
5 
(3
1.
9)
84
 (
35
.9
)
11
9 
(4
0.
1)
12
 (
44
.4
)
,
0.
00
1
O
be
si
ty
BM
I ,
18
.5
 k
g/
m
2
47
 (
3.
2)
11
 (
1.
7)
21
 (
3.
0)
15
 (
18
.9
)
,
0.
00
1
24
 (
3.
6)
7 
(2
.4
)
12
 (
3.
5)
5 
(1
4.
3)
,
0.
00
1
18
.5
 k
g/
m
2 
#
 B
M
I ,
23
.0
 k
g/
m
2
98
0 
(6
8.
3)
49
2 
(7
2.
6)
44
0 
(6
6.
3)
48
 (
64
.9
)
46
5 
(6
9.
0)
20
9 
(7
2.
1)
23
1 
(6
6.
6)
25
 (
71
.4
)
0.
01
5
23
.0
 k
g/
m
2 
#
 B
M
I
41
7 
(2
9.
1)
17
1 
(2
5.
8)
23
4 
(3
3.
7)
12
 (
16
.2
)
18
3 
(2
7.
2)
74
 (
25
.5
)
10
4 
(3
0.
0)
5 
(1
4.
3)
,
0.
00
1
O
st
eo
po
ro
si
sb
O
st
eo
pe
ni
a
22
 (
1.
7)
6 
(1
.0
)
15
 (
2.
4 
)
1 
(1
.4
)
0.
25
6
29
 (
4.
9)
13
 (
4.
9)
14
 (
4.
7)
2 
(5
.9
)
0.
86
2
O
st
eo
po
ro
si
s
13
 (
1.
0)
2 
(0
.3
)
2 
(0
.3
)
9 
(1
2.
5)
30
 (
5.
0)
10
 (
3.
8)
18
 (
6.
0)
2 
(5
.9
)
O
st
eo
ar
th
ri
tis
b
11
7 
(8
.9
)
65
 (
10
.5
)
47
 (
7.
6)
5 
(6
.9
)
,
0.
00
1
10
9 
(1
8.
3)
56
 (
21
.3
)
51
 (
17
.0
)
2 
(5
.9
)
,
0.
00
1
N
ot
es
: D
at
a 
ar
e 
pr
es
en
te
d 
as
 n
um
be
rs
 (
pe
rc
en
ta
ge
s)
 fo
r 
ca
te
go
ri
ca
l v
ar
ia
bl
es
. a
T
he
 s
um
s 
of
 s
om
e 
da
ta
 d
o 
no
t 
eq
ua
l t
he
 t
ot
al
 d
ue
 t
o 
m
is
si
ng
 d
at
a.
 b
D
at
a 
do
 n
ot
 e
qu
al
 t
he
 t
ot
al
 b
ec
au
se
 e
va
lu
at
io
ns
 fo
r 
os
te
op
or
os
is
 a
nd
 o
st
eo
ar
th
ri
tis
 
w
er
e 
on
ly
 p
er
fo
rm
ed
 in
 s
ub
je
ct
s 
ag
ed
 $
50
 y
ea
rs
 (m
al
e,
 o
bs
tr
uc
tiv
e 
=1
,3
08
; m
ild
 =
61
9;
 m
od
er
at
e 
=6
17
; s
ev
er
e 
=7
2;
 fe
m
al
e,
 o
bs
tr
uc
tiv
e 
=5
97
; m
ild
 =
26
3;
 m
od
er
at
e 
=3
00
; s
ev
er
e 
=3
4)
; n
or
m
al
 =
 F
eV
1/F
V
C
 $
70
%
 a
nd
 F
eV
1 $
80
%
 p
re
di
ct
ed
; 
re
st
ri
ct
iv
e 
= 
Fe
V
1/F
V
C
 $
70
%
 a
nd
 F
eV
1 ,
80
%
 p
re
di
ct
ed
; o
bs
tr
uc
tiv
e 
= 
Fe
V
1/F
V
C
 ,
70
%
 p
re
di
ct
ed
; m
ild
 =
 F
eV
1 $
80
%
 p
re
di
ct
ed
; m
od
er
at
e 
=5
0%
 #
 F
eV
1 ,
80
%
 p
re
di
ct
ed
; s
ev
er
e 
= 
Fe
V
1 ,
50
%
 p
re
di
ct
ed
.
A
bb
re
vi
at
io
ns
: B
M
I, 
bo
dy
 m
as
s 
in
de
x;
 D
M
, d
ia
be
te
s 
m
el
lit
us
; F
eV
1, 
fo
rc
ed
 e
xp
ir
at
or
y 
vo
lu
m
e 
in
 1
 s
ec
on
d;
 F
V
C
, f
or
ce
d 
vi
ta
l c
ap
ac
ity
; h
D
l,
 h
ig
h 
de
ns
ity
 li
po
pr
ot
ei
n;
 l
D
l,
 lo
w
 d
en
si
ty
 li
po
pr
ot
ei
n.
International Journal of COPD 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1577
Comorbidities in obstructive lung disease in Korea
$ 




+\
SHU
WHQV
LRQ

'LD
EHWH
VP
HOOLW
XV

%0
,


%0
,


2VW
HRD
UWKU
LWLV












'
(
&
%






 
  


  
 


1RUPDO



 





 



0LOG 0RGHUDWH
2EVWUXFWLYH
6HYHUH 1RUPDO 0LOG 0RGHUDWH
2EVWUXFWLYH
6HYHUH
1RUPDO 0LOG 0RGHUDWH
2EVWUXFWLYH
6HYHUH1RUPDO 0LOG 0RGHUDWH
2EVWUXFWLYH
6HYHUH







 



 1RUPDO 0LOG 0RGHUDWH
2EVWUXFWLYH
6HYHUH
0HQ :RPHQ
Figure 2 Prevalence of hypertension (A), DM (B), underweight (C) and overweight (D), and osteoarthritis (E) by sex and severity of obstructive airflow limitation.
Notes: normal = FeV1/FVC $70% and FeV1 $80% predicted; obstructive = FeV1/FVC ,70%; mild = FeV1 $80% predicted; moderate =50% # FeV1 ,80% predicted; severe 
FeV1 ,50% predicted.
Abbreviations: BMI, body mass index; DM, diabetes mellitus; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
increasing age and smoking are the most important factors 
in COPD. In this study, the prevalence of hypertension was 
49.6%. Moreover, the findings showed that the prevalence 
of hypertension increases with the severity of obstruction, 
regardless of sex (Figure 2A).
DM occurs frequently in COPD and is being increasingly 
reported in many studies, and the prevalence is reported as 
approximately 10%–25%.12,23,24,29 The association between 
the two diseases is not identified precisely, although it is 
believed to be a consequence of systemic inflammation.30 
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DM in patients with COPD is caused partly by common 
genetic, lifestyle, and environmental factors, as well as the 
use of systemic corticosteroids, which are used to control 
lung inflammation in COPD.31,32 In a previous study in Korea, 
the prevalence of DM was shown to be 16.6%.15 DM has 
no correlation with the severity of airflow limitation, and 
is more common in men.25 In this study, the prevalence of 
DM was 16.8%, and it was more common depending on the 
severity (except in the severe group), while it showed less 
prevalence in females (Figure 2B). Low prevalence of DM 
in COPD can be affected by low BMI,33 which increases in 
patients with severe airway obstruction.
Dyslipidemia is one of several parameters employed to 
diagnose metabolic syndrome. A previous study reported that 
the prevalence of dyslipidemia in COPD was approximately 
36%–52%.23,27 Dyslipidemia is one of the major comorbidi-
ties in COPD; however, most studies have not demonstrated 
differences in the prevalence of dyslipidemia between COPD 
and control subjects.34 Otherwise, Joo et al15 reported that 
the prevalence of dyslipidemia in COPD was 31.7%, which 
was lower than that in non-COPD subjects. They defined 
dyslipidemia as an LDL cholesterol level $130 mg/dL. In 
our study, the prevalence of dyslipidemia was 72.7%, which 
was higher than that in the normal lung function group. This 
difference is rooted in the definition of dyslipidemia. As in the 
previous study, our study showed that high LDL cholesterol 
was less common in the obstructive lung function group than 
in the normal lung function group. However, the prevalence 
of hypertriglyceridemia and low HDL cholesterol was higher 
in the obstructive lung function group than in the normal lung 
function group. Characteristically, the prevalence of all forms 
of dyslipidemia decreased in the severe group (Table 2). This 
phenomenon appears prominently in men. Low BMI would 
have a profound influence on results. A general increasing 
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trend marks the prevalence of dyslipidemia, with increas-
ing BMI in both men and women with age.35,36 However, 
in women, it increased rather than decreased in the severe 
group, despite a finding that underweight was predominant 
in the severe obstructive lung function group (Figure 3). This 
might be due to the mild severity of airway obstruction and 
racial/ethnic differences,37 or the low percentage of smokers 
and old age in female COPD patients.
Anemia is usually seen in 10%–30% of COPD 
patients.38 Anemia is a cause of dyspnea and contributes 
to functional limitation in anemic patients. The mecha-
nism by which patients with COPD develop anemia 
remains unclear. Systemic inflammation, neurohormonal 
activation – both of which are associated with smoking – 
and cardio–renal syndrome, which involves activation of 
the renin–angiotensin–aldosterone system, were thought 
to be the mechanisms causing anemia in COPD patients.39 
In Korea, the prevalence of anemia in the obstructive lung 
function group was previously found to be 7.6%; our study 
also showed a prevalence of 7.6%. John et al40 reported that, 
because of hypoxia, patients with advanced COPD showed 
significantly higher hemoglobin values and lower prevalence 
of anemia than did patients with COPD in stage 0. In our 
study, there was no association with severity in both men 
and women. Mean hemoglobin level was approximately 
14.9–15.0 g/dL in men, and approximately 13.0–13.3 g/dL 
in women at all stages of obstruction. Moreover, there was 
no difference in the prevalence of anemia relative to the 
severity of COPD. These prevalence findings may be contin-
gent upon patient characteristics and the diagnostic criteria 
used.41 Women were significantly more likely than men to 
be anemic (6.2% vs 9.5%); when the subject population was 
divided into men and women, women from the obstructive 
lung function group did not show differences from the normal 
lung function group (men: 3.7% vs 6.2%; P,0.001, women: 
11.8% vs 9.5%; P,0.306). We considered that the effects 
of other causes (eg, menopause, other chronic diseases) are 
more clinically important than those of systemic inflamma-
tion of COPD in women $40 years old. Further studies are 
needed on this topic. To our knowledge, this is the first study 
to have mentioned the relationship between anemia, severity 
of COPD, and sex.
Osteoporosis is a major comorbidity in COPD.7 It is 
also associated with poor health status and prognosis. 
Osteoporosis is more common in subjects with low BMI 
and low fat-free mass.42,43 A higher GOLD stage and a low 
FEV
1
 have been shown to be related to osteoporosis in the 
presence of low bone mineral density (BMD).44,45 Physical 
inactivity, smoking, poor diet, and systemic corticosteroids 
seem to have important effects on osteoporosis. Again, sys-
temic inflammation in COPD patients can be a risk factor in 
osteoporosis.46 The prevalence of osteoporosis in COPD is 
8.4%–69%, and the prevalence of osteopenia is 28%–67%.47 
In Korea, an osteoporosis prevalence of 7.9% was reported 
in COPD patients.15 This difference may be due to differ-
ences in patient characteristics and ethnicity. Our study also 
showed a high prevalence of osteoporosis among patients 
in the severe obstructive lung function group. However, the 
prevalence of osteopenia was lower than that in the normal 
lung function group (Table 2). Because the number of cases 
of osteopenia and osteoporosis in the severe obstructive lung 
function group was too small for accurate determination, it 
is necessary to perform studies with more subjects.
There are some studies that have reported the associa-
tion between COPD and arthritis. The rate of osteoarthritis 
in patients with COPD has been shown to be 22%–70%.48,49 
In almost all of these studies, arthritis was defined via self-
report, or the researchers studied only rheumatic arthritis. 
A previous study in Korea found no association between 
arthritis and COPD, although that study was dependent upon 
questionnaires.15 Our study excluded the subjective symptoms 
of the patient, and diagnosed arthritis by using a radiological 
objective image; 11.9% of COPD subjects had osteoarthritis. 
More than half (61.1%) of these cases were accompanied by 
symptoms (data were not shown). To our knowledge, this is 
the first study that has mentioned the relationship between 
osteoarthritis, severity of COPD, and sex.
In this study, we investigated the relationship between 
COPD airflow limitation severity and comorbidities with 
objective measurements. Echave-Sustaeta et al50 mentioned 
that severity is not an independent predictor of comorbidity. 
However, we showed that many comorbidities were associ-
ated with severity. Our study had several strengths. First, 
we used data from a nationwide survey, with a nationally 
representative stratified random sample that was comprised 
of various objective data points. Thus, we could use a much 
larger sample size than other studies. We also obtained the 
data on comorbidities (eg, arthritis, osteroporosis) by labo-
ratory tests and image study, not only interviews. Second, 
to our knowledge, this is the first study that was analyzed 
separately for both sex and severity. Third, we did not exclude 
restrictive lung disease subjects. Therefore, our study showed 
characteristics of the subjects with restrictive lung disease.
However, this study had some limitations. First, although 
this was a prevalence study of comorbidities in COPD, there 
was no analysis about other important comorbidities such as 
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cardiovascular disease and cancer because no objective data 
were available regarding these diseases. While previous stud-
ies of COPD comorbidities were based on interviews, this 
study was carried out on the basis of laboratory tests, image 
studies, and physical examination. Even though question-
naires included questions on the history of cardiovascular 
disease, depression, lung cancer, pulmonary tuberculosis, 
asthma, and allergic rhinitis, they were not objective. For 
that reason, we did not use this information in our study. So 
we just described these comorbidities according to a self-
reported questionnaire on Table S1. Second, we included 
subjects with airway obstruction caused by other diseases, 
such as pulmonary tuberculosis, bronchiectasis, and asthma. 
This could have overdetermined the number of subjects with 
airway obstruction. Third, our spirometry data were prebron-
chodilator spirometry data. Fourth, disease severity in most 
subjects with airway obstructive disease was classified as 
either mild or moderate. When divided into men and women, 
many parameters had fewer than five subjects in the severe 
airway obstructive lung disease group, a circumstance that 
could have affected the result.
Conclusion
In conclusion, this study showed that hypertension and under-
weight are common comorbid diseases in COPD patients, 
and are more increased as the severity of airflow obstruction 
increased in both men and women. DM, hypertriglyceri-
demia, and low HDL cholesterol are also more common in 
subjects with airway obstruction, although their prevalence 
is lower in subjects with severe airway obstruction.
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Table S1 Comorbidities according to self-reported questionnaire
Comorbidity Normal Restrictive Obstructive Obstructive severity P-value
Mild Moderate Severe
12,224 (75.6%) 1,819 (11.3%) 2,108 (13.1%) 954 (45.3%) 1,042 (49.4%) 112 (5.3%)
Cardiovascular disease
Ischemic heart disease 321 (2.6) 82 (4.5) 80 (3.8) 33 (3.5) 43 (4.1) 4 (3.6) ,0.001
angina pectoris 238 (1.9) 53 (2.9) 44 (2.1) 20 (2.1) 22 (2.1) 2 (1.8) 0.037
Myocardial infarction 101 (0.8) 33 (1.8) 38 (1.8) 14 (1.5) 22 (2.1) 2 (1.8) ,0.001
stroke 118 (1.0) 64 (3.5) 63 (3.0) 28 (2.9) 30 (2.9) 10 (8.9) ,0.001
Depression 1,922 (15.7) 289 (15.9) 265 (12.6) 115 (12.1) 130 (12.5) 20 (17.9) ,0.001
lung cancer 3 (0.0) 7 (0.4) 9 (0.4) 1 (0.1) 7 (0.7) 1 (0.9) ,0.001
Pulmonary tuberculosis 604 (4.9) 163 (9.0) 229 (10.9) 92 (9.6) 168 (16.1) 39 (34.8) ,0.001
asthma 366 (3.0) 108 (5.9) 273 (13.0) 67 (7.0) 153 (14.7) 53 (47.3) ,0.001
allergic rhinitis 415 (3.4) 74 (4.1) 67 (3.2) 24 (2.5) 41 (3.9) 2 (1.8) 0.734
Notes: Data are presented as numbers (percentages) for categorical variables. normal = FeV1/FVC $70% and FeV1 $80% predicted; restrictive = FeV1/FVC $70% and 
FeV1 ,80% predicted; obstructive = FeV1/FVC ,70% predicted; mild = FeV1 $80% predicted; moderate =50% # FeV1 ,80% predicted; severe = FeV1 ,50% predicted.
Abbreviations: FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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